DEA files a brief rejecting further testimony or discovery in the marijuana rescheduling hearing, declaring opponents’ request a fishing expedition. The agency’s brief, filed on Tuesday, also opposes any additional briefings on the matter.
DEA Rebuffs Request to Reopen Hearing
The agency’s latest brief, filed on Tuesday, says the Government Accountability Office report contains no new evidence and that the Administrative Procedure Act bars supplemental record‑making after testimony has closed. It argues that the GAO report’s gaps do not justify extra discovery.
DEA argues that opponents seek broad discovery—including six years of GAO requests and extensive witness depositions—far beyond the narrow issues already addressed at the hearing. Such requests would exceed the scope of the existing record.
Judge Derek Julius has not yet decided whether to admit the GAO report, which concluded that DEA and the FDA lack formal policies or procedures for evaluating and scheduling controlled substances. The judge’s decision remains pending.
The rescheduling opponents—National Drug & Alcohol Screening Association, DUID Victim Voices and Kenneth Finn—requested permission to file a response, asserting that the GAO’s finding of missing procedural records is material, not immaterial. They claim the procedural deficiencies undermine the legitimacy of the rescheduling process.
DEA counters that the GAO document merely identified gaps in memorialization, not deficiencies in the rescheduling process itself, and urges the judge to defer to the ten‑month HHS scientific study recommending Schedule III. DEA maintains that existing evidence supports its position.
In its brief, DEA cites more than 30,000 prescribers treating six million patients across 43 states, saying these practices demonstrate accepted safety and rule out Schedule I classification. The data illustrate a robust medical use pattern nationwide.
The agency adds that substantial evidence links marijuana’s abuse and dependency profiles to Schedule III, reinforcing its claim that the plant no longer fits Schedule I criteria. Regulators therefore view it as comparable to Schedule III substances.
The hearing featured testimony from an FDA scientist and a New Hampshire physician on medical benefits and relative safety, while opponents highlighted potential harms and criticized updated medical‑value analysis methods. Their arguments focus on alleged health risks rather than procedural issues.
DEA barred pro‑reform participants from the hearing, prompting activists to demand livestream access; a congressman and several journalists later joined that request. The hearing itself was not streamed to the public.
The rescheduling effort is entangled in a federal appeals‑court consolidation that includes lawsuits filed by state attorneys general, marijuana opponents and a cannabis biotech firm. The case is being heard amid ongoing litigation challenges.
The D.C. Circuit recently rejected a motion to block the Trump administration’s progress, and a congressional committee voted to halt further rescheduling steps, though insiders say the measure is unlikely to become law. Lawmakers say the congressional vote is unlikely to affect the agency’s next steps.
DEA asks Judge Julius to expedite his recommendation to move marijuana from Schedule I to Schedule III. A prompt ruling would move the policy forward toward Schedule III.
